Kura Oncology reports Phase 1a data on darlifarnib combo in RCC

Go back to Kura Oncology reports Phase 1a data on darlifarnib combo in RCC
(NASDAQ: KURA) Delayed: 9.67 +0.06 (0.62%)
Previous Close $9.61    52 Week High $8.90 
Open $9.73    52 Week Low $2.50 
Day High $9.84    P/E N/A 
Day Low $9.62    EPS $0.00 
Volume 193,746